# A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat

Source: https://onco.cc/trials/nct06797297/  
OnCo record `nct06797297` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IBI363, Pembrolizumab in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy is a phase 2 interventional study registered as NCT06797297 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2025-02-24 and due to reach its primary completion in 2026-03-31. Interventions recorded: IBI363, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06797297
- Phase: 2
- Setting: A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06797297: https://clinicaltrials.gov/study/NCT06797297

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IBI363](https://onco.cc/drugs/ibi363/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct06797297.json